ABSTRACT
INTRODUCTION
Prostate cancer (PCa) is the most common cancer in males in the United States and the second leading cause of cancer-related deaths in men (1) . Due to the heterogeneous nature of PCa progression, there is a growing need to identify biomarkers to aid in early prognostic risk stratification. While many men now present to the clinic with indolent, non-aggressive tumors due to the widespread screening of prostate-specific antigen (PSA) levels, identifying patients whose tumors will progress into aggressive phenotypes and whose tumors may recur following radical prostatectomy both remain critical concerns in PCa care (2) .
Temperature can be an important element of the physical microenvironment that can regulate cellular stem cell-like properties, especially in the context of cancer (3) . Temperature effects are modulated at the cellular level by stress-response pathways that include heat-shock and cold-shock proteins (4) (5) (6) . In contrast to heat-shock proteins (HSP), which are induced by increased temperatures, cold-shock proteins (CSP) are induced by low temperatures but are downregulated when temperatures are elevated (5, 7) . The RNA-binding motif protein 3 (RBM3) is a glycine rich protein with an RNA recognition motif capable of binding to both RNA and DNA and is one of the earliest proteins synthesized in response to cold shock (4) . The role of RBM3 as a putative cancer biomarker was originally unraveled using an antibody-based discovery approach (www.proteinatlas.org) (8) (9) (10) . RBM3 is an evolutionarily conserved CSP that has been shown to regulate the translation machinery and facilitate protein synthesis during hypothermic stress and in brain development, where it functions as an RNA chaperone to maintain RNA stability (11, 12) . Recent studies have suggested that RBM3 has a potential proto-oncogenic function and has been found to be up-regulated in various types of human malignancies, including breast, prostate, ovarian, pancreatic, colorectal, and skin (13) (14) (15) (16) . Further, RBM3 has been specifically shown to have elevated nuclear expression in many cancer types and accumulating evidence has associated this expression with prolonged times to biochemical recurrence (BCR) and clinical tumor progression in the PCa setting (17) . In a recent study that used a gene set enrichment analysis to elucidate the role of RBM3 in underlying biological processes, increased RBM3 expression was associated with DNAdependent replication, chromatin remodeling, and DNA damage response mechanisms (18) .
It is well established that nuclear alterations are a hallmark of many types of cancers, including PCa (19) . During cancer progression, alterations to the genetic, epigenetic, and tumor microenvironmental landscape result in significant changes to the nucleus of cancer cells, including size and shape changes, textural changes, and spatial changes in the context of the surrounding cells. Genetic and epigenetic variations during cancer are thought to drive large-scale nuclear alterations during cancer progression. Specifically, it is believed that three-dimensional chromatin organizational alterations and altered methylation patterns have important ramifications for altered gene expression profiles and DNA stability in cancer cell nuclei. Through connections mediated by the nuclear lamina and nuclear matrix, three-dimensional chromatin changes can contribute to nuclear pleomorphism in cancer cells.
Given that RBM3 has been hypothesized to play a role in critical nuclear functions such as chromatin remodeling, DNA damage response, and other post-transcriptional processes, we sought to: (1) further elucidate RBM3 expression in archival PCa samples; (2) develop a nuclear morphometric model to see if measures of RBM3 expression levels and nuclear features could be used to predict disease aggressiveness and BCR; and (3) assess the correlation between RBM3 expression and nuclear architectural features, thus providing an insight into how RBM3 is involved in nuclear alterations.
MATERIALS AND METHODS

Immunohistochemical
Tissue Microarray Preparation Two tissue microarrays (TMAs) were obtained from the Prostate Cancer Biorepository Network (PCBN) at the Johns Hopkins Hospital (JHH; Baltimore, MD). Samples for TMAs were obtained from biopsy samples obtained at JHH from 2002-2011 following IRB approval. Each TMA sample includes four replicates of 0.60mm punched cores. The TMAs were prepared using a Beecher MT1 manual arrayer (Beecher Instruments, Silver Spring, MD) in the TMAJ pathology core facility at the PCBN and processed as previously described (20, 21) . In brief, TMA samples were incubated with anti-RBM3 antibody produced in rabbit (Sigma; Product Number HPA003624) at a 1:200 dilution for 1 hour at room temperature followed by an overnight incubation at 4°C. Secondary anti-rabbit antibody conjugated with horseradish peroxidase (KPL/SeraCare, Milford, MA) was incubated with the samples at a 1:200 dilution. The slides were subsequently stained with hematoxylin and cover-slipped with Vector Mount.
Prostate Cancer Cohort
The stained slides from each TMA were reviewed and graded by an expert uropathologist. Among the 80 cases in this cohort (40 cases from each TMA), 10 were scored as Gleason sum (GS) 3+3 disease, 20 were scored as GS 3+4, 20 were scored as GS 4+3 disease, and 30 were scored as GS ≥ 8 disease. Further, 20 out of 80 total cases exhibited BCR, which was defined as having a prostate-specific antigen (PSA) level increase greater than 0.2 ng/mL following surgery. Patients with BCR had a mean follow-up time of 8.9 years (median: 10 years; range: 3-13 years). Patients that did not experience BCR had a mean follow-up time of 5.3 years (median: 3 years; range: 1-12 years). The complete and detailed clinicopathologic demographics of the TMA are found in Table 1 .
Nuclear Morphometric Analysis
A customized image processing algorithm was created using semi-quantitative methods supported by the ImagePro Premier 9.1 software package (Media Cybernetics, Rockville, MD) to segment and quantify RBM3-stained nuclei in each TMA core image. The algorithm was trained to identify nuclear features from RBM3-positive glandular epithelial cell nuclei by using band-pass filtering for size, color, and intensity. In RBM3-positive nuclei, twenty-two different nuclear features were determined and recorded, including measures of nuclear size and shape and RBM3 staining intensity. One softwarederived feature, Integrated Optical Density (IOD), was used as a measure of antibody staining intensity and was therefore used to estimate RBM3 protein content as previously performed (21, 22) . Using a subset of the most prognostic features (as determined using univariate logistic regression modeling), a multivariate logistic regression (MLR) model was generated to determine if measures of RBM3 staining intensity and nuclear structural changes could be used to distinguish more aggressive (GS 4+3 and GS ≥ 8 disease) PCa from less aggressive (GS 3+3 and GS 3+4) PCa. The same set of significant features was then used in a separate MLR model to determine if they could be used to identify patients who exhibited BCR against those that did not.
Statistical Analysis
Prior to generating the MLR models to identify aggressive PCa and BCR cases, univariate logistic regression was first performed to identify which features were individually prognostic of aggressive PCa. Using the features that showed univariate significant prognostic capabilities (P < 0.05), the MLR models for aggressive PCa prediction and BCR prediction were then generated. Due to the small sample sizes, leave-one-out cross validation (LOOCV) was used to provide insight on how the predictive capabilities of the feature set might behave with respect to an independent patient cohort to address issues such as model overfitting. Statistical significance was defined as P < 0.05. Non-parametric Mann-Whitney U tests were used for all group comparison analyses. Correlations of RBM3 staining intensity with the measures of nuclear structural changes that were in the MLR model were evaluated using Spearman's rank correlation coefficients. GraphPad Prism 7 (GraphPad Software, La Jolla, CA) was used to generate all graphs. STATA 13.0 (StataCorp LLC, College Station, TX) was used for all univariate and multivariate modeling and analysis as well as for the LOOCV approach.
RESULTS
RBM3 is down regulated in aggressive PCa and biochemical recurrent patient samples
Two TMAs containing a total of 80 PCa patient samples were stained for the RBM3 protein. Nuclear features were quantified using the ImagePro Premier 9.1 software. Images of the TMA cores confirmed the nuclear localization of the RBM3 protein ( Figure 1A) . In order to quantify RBM3 staining intensity in TMA images, the IOD measurement was identified as the most favorable due to its quantification of staining luminance over a given pixel area, an approach previously used by our group (20) . The IOD measure of staining intensity from TMA images was used as a measure of RBM3 protein expression. Interestingly, when comparing IOD levels across samples of various Gleason scoring, RBM3 showed a significant downregulation in samples with a GS ≥ 8 compared to GS 3+3 samples (P = 0.0018), GS 3+4 samples (P = 0.0001), and GS 4+3 samples (P = 0.0006) ( Figure 1B) . Similarly, significantly lower levels of RBM3 were observed in BCR cases compared to those that showed no disease recurrence (P = 0.0377).
MLR model distinguishes aggressive PCa phenotype
From the original set of twenty-two nuclear morphometric features that were extracted from the RBM3-positive cancer nuclei, univariate logistic regression revealed that in addition to the IOD for the quantification of the RBM3 staining intensity, ten of the nuclear architectural features were individually significant (P < 0.05) for predicting an aggressive PCa phenotype (GS 4+3 and GS ≥ 8 cases). The full results from the univariate logistic regression for each feature can be found in Supplementary File 1. Table 2 highlights the significant features and their descriptions with respect to quantifying a measure of nuclear architecture or staining intensity. These eleven features were then combined to generate a MLR model for the prediction of aggressive PCa. In the raw data set, this eleven-feature MLR model was significantly predictive for distinguishing aggressive PCa cases from less aggressive cases and yielded a receiver operating characteristic area under the curve (ROC-AUC) of 0.90 (P < 0.0001; 95% CI: 0.83-0.97) (Figure 2A ). LOOCV using the eleven features for prediction of aggressive PCa confirmed the predictive capability of the feature set, yielding a The eleven-feature MLR model further distinguishes BCR patient samples We then sought to determine if the same set of eleven features could be used to identify patients with BCR. MLR modeling for prediction of BCR yielded a ROC-AUC = 0.92 (P = 0.0004; 95% CI: 0.85-0.98) ( Figure 3A ) in the raw data set. LOOCV using the eleven features for prediction of BCR confirmed the predictive capability of the feature set, yielding a ROC-AUC of 0.76 (95% CI: 0.64-0.87). The predictive probability plot of the LOOCV results further shows the significant separation in the BCRnegative and BCR-positive cases (P = 0.0008) ( Figure  3C ). Additionally, we evaluated the ability of the eleven-feature model to predict BCR compared to the currently used Gleason scoring system ( Figure  3D ). The ROC-AUC of the eleven-feature model showed comparable performance to the Gleason sum (ROC-AUC = 0.73) for predicting BCR cases (P = 0.70) ( Figure 3D) .
A file showing the STATA code and STATA outputs from the generation of the MLR model and LOOCV testing to predict BCR can be found in Supplementary File 3.
RBM3 protein staining intensity correlates significantly with features from the MLR model
We evaluated the correlation between RBM3 staining intensity (as represented by the IOD feature) and the other ten univariately significant features from the aggressive and BCR MLR models. We found that RBM3 expression exhibited significant associations with the features with varying degrees of strength of correlation relationships. This included area (Spearman rho = 0.92; P < 0.0001), axis major (Spearman rho = 0.82; P < 0.0001) ( Figure 4A Figure 4I ). With the strong positive correlations observed here, similar relationships between RBM3 staining and the model parameters were observed as seen in Figure 1B (i.e. as RBM3 expression decreased in higher Gleason score tumors, similar decreases in maximum diameter, for example, also occurred).
DISCUSSION
The RBM3 protein has previously been shown to be upregulated in a wide range of cancer types, including prostate, melanoma, colorectal, breast, and ovarian (14, 16-18, 23, 24) as compared to benign tissues.Overexpression of the nuclear RBM3 protein has been associated with significantly improved survival (16, 17) . In particular, in the context of PCa, patients with tumors expressing high nuclear levels of RBM3 have a significantly prolonged time to BCR and clinical progression (17) . Our study attempts to further clarify the role of RBM3 in PCa by examining its protein expression in a cohort of archival PCa samples with varying Gleason scores and BCR statuses. Further, given the high levels of nuclear localization for RBM3, we sought to determine if RBM3 protein levels in conjunction with other nuclear features could stratify patients that had aggressive (GS 4+3 and GS ≥ 8) PCa and BCR based on changes in RBM3 levels and altered nuclear architectural features. While previous studies have focused on RBM3 expression using only staining intensity by immunohistochemical studies, this study provides the first evaluation of RBM3 in the context of nuclear morphometric changes within human PCa cells. We show that these features can be combined to predict PCa aggressiveness and BCR status.
Previous immunohistochemical analysis of RBM3 first uncovered upregulated RBM3 expression in prostatic intraepithelial neoplasia and invasive prostate tumor samples (17) as compared to benign samples. While this effect was not quantified across various Gleason scores, the same study showed high nuclear expression was specifically associated with improved clinical outcomes (i.e. increased time to BCR and disease progression) compared to a lowexpressing RBM3 group. Our study examined RBM3 levels across PCa samples of varying Gleason scores and interestingly found that significantly lower RBM3 levels were discovered in higher Gleason score tumors. Further, RBM3 levels were significantly downregulated in PCa that displayed BCR versus those that didn't. In contrast with our results is a study that showed high RBM3 expression was associated with high Gleason score and advanced tumor stage (23). Notably, RBM3 expression was also related to early BCR. The discrepancy in these results may be attributable to the fact that these previous studies used a categorical descriptor of RBM3 staining intensity. Our study used a continuous variable derived from the image processing software, Integrated Optical Density, which may substantiate our results in comparison to categorical measures of staining intensity from the human eye. While our PCa cohort lacked longitudinal survival data, our results suggest that the high RBM3 nuclear expression in low Gleason score tumors, which are typically less aggressive and associated with longer times to BCR, have validity. This result is further substantiated by a 2013 study that showed decreased RBM3 expression in metastatic PCa samples, a finding that suggests that RBM3 upregulation may be important for the early oncogenic events leading to PCa while RBM3 downregulation may have ramifications for progression and metastasis (25) . Given that our study further clarifies that RBM3 has a tumor inhibitory role with lower expression levelsin high Gleason score PCa, there now seems to be a growing consensus that RBM3 could be a putative biomarker for PCa. While RBM3 has not previously been shown to be present in the serum or urine of PCa patients, perhaps RBM3 staining of a diagnostic biopsy or a surgery sample could provide insight into tumor behavior and aid clinicians into predicting tumor aggressiveness or potential for BCR.
Our data shows that RBM3 staining, in addition to nuclear morphometric features, is predictive of aggressive prostate cancer and biochemical recurrence. The prediction of biochemical recurrence using our novel 11-feature model is slightly better (though not statistically significant) to the currently used Gleason score. We believe a potential application for nuclear morphometry modeling is to aid pathologists in their grading of prostate cancer. Currently, Gleason scoring, which is based on a pathologist's subjective grading, is the best way to predict prostate cancer progression. Even among specialists and expert uropathologists, discrepancies in determining tumor grade and Gleason scoring are significant as prostate cancer is known to have high glandular and nuclear heterogeneity (26) . Manual grading remains a laborious process, often resulting in poor score reproducibility between pathologists. Computeraided approaches can ameliorate many of these challenges by providing an objective algorithm that can track both biomarker staining (not limited to RBM3) as well as sub-visual nuclear changes that a pathologist may not recognize at eye level (27) . Further, our eleven-feature can add clinical value by providing a faster, more efficient method to predict tumor progression (both aggressiveness and potential biochemical recurrence) and aid pathologists in their assessment of tissue samples. Our data shows that it compares favorably to the currently used method and could be feasible method to use clinically. Our study was limited in that our overall sample size (N = 80) and the number of samples that exhibited BCR (N = 20) was small. This prevents large-scale applicability of the results beyond the samples included in the study. Given the lack of an independent dataset to test our model, this study warrants further external validation in anlarger TMA set. However, we employed leave-one-out crossvalidation to address the potential overfitting that may have occurred due to the small sample sizes and to provide a measure of internal validation. Our LOOCV results showed the strength of our elevenfeature model for predicting both aggressiveness and BCR. A decrease was observed in the ROC-AUC from the raw data to the LOOCV results for both the aggressiveness and BCR models. We attribute this to the small sample sizes, but the LOOCV tests still exhibit strong predictive ability. In the case of the BCR model specifically, the model still compared favorably with the currently-used Gleason sum for predicting which patients will experience BCR and adds the efficiency that a computational approach adds over the currently used manual grading system. In addition to the sample sizes, the lack of survival data with our samples limits comparisons with existing studies which examine RBM3 in the context of time to BCR or clinical progression. Further studies to assess our eleven-feature model predicting overall survival or time to BCR are warranted. We believe that having a single, eleven-feature model for predicting both aggressiveness and BCR is a strength of the study. While there are a multitude of potential nuclear features to track in a MLR model, having the same eleven features in both models strengthens the case for testing in future studies in independent samples to further assess applicability. Dr. Prakash Kulkarni (Institute for Bioscience and Biotechnology Research, University of Maryland) for his insightful feedback and comments of the manuscript drafts. The project described was supported by National Center for Research Resources and National Cancer Institute grant U54CA143803 (RWV and Donald Coffey, Co-PIs) and the Prostate Cancer Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. The funders had no role in the study design, the collection, analysis, and interpretation of data, involvement in drafting the manuscript, or decision to submit the manuscript for publication. 
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